No CrossRef data available.
Article contents
Use of atrial flow regulator device in children and patients with CHD: a literature review
Published online by Cambridge University Press: 11 September 2025
Abstract
The Occlutech Atrial Flow Regulator is a self-expandable double-disc nitinol device with a central fenestration designed to create a calibrated communication across the interatrial septum. It has been used in adult patients with heart failure and pulmonary hypertension. Its use in the paediatric population or adults with CHD has been published in several case reports and case series. This study aims to review the potential, efficacy, and safety of this device in the paediatric and adult populations living with CHD, as well as in paediatric patients with pulmonary hypertension or advanced heart failure.
Keywords
Information
- Type
- Review
- Information
- Copyright
- © The Author(s), 2025. Published by Cambridge University Press
References
Paitazoglou, C, Bergmann, MW, Özdemir, R, Pfister, R, Bartunek, J, Kilic, T, et al. AFR-PRELIEVE investigators. One-year results of the first-in-man study investigating the atrial flow regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study. Eur J Heart Fail 2021; 23: 800–810.CrossRefGoogle Scholar
Shah, SJ, Borlaug, BA, Chung, ES, Cutlip, D, Debonnarie, P, Fail, PS et al. REDUCE LAP-HF II investigators. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. Lancet 2022; 399: 1130–1140.CrossRefGoogle Scholar
Dąbrowska-Kugacka, A, Ciećwierz, D, Żuk, G, et al. Atrial flow regulator for severe drug-resistant pulmonary arterial hypertension after congenital heart defect correction. Cardiol J 2019; 26: 102–104.CrossRefGoogle ScholarPubMed
Sivakumar, K, Rohitraj, GR, Rajendran, M, Thivianathan, N. Study of the effect of occlutech atrial flow regulator on symptoms, hemodynamics, and echocardiographic parameters in advanced pulmonary arterial hypertension. Pulm Circ 2021; 11: 2045894021989966.CrossRefGoogle ScholarPubMed
Vanhie, E, VandeKerckhove, K, Haas, NA, De Wolf, D. Atrial flow regulator for drug-resistant pulmonary hypertension in a young child. Catheter Cardiovasc Interv 2021; 97: E830–E834.Google Scholar
Atrial flow regulator in heart failure (PROLONGER). Clinicaltrials.gov identifier: NCT04334694. Accessed January 10, 2023. https://clinicaltrials.gov/ct2/show/NCT04334694
Google Scholar
The Prophet Trial-Pilot study to assess the safety and efficacy of a novel Atrial Flow Regulator (AFR) in patients with pulmonary hypertension (AFR-Prophet). Clinicaltrials.gov identifier: NCT03022851. Accessed January 10, 2023. https://clinicaltrials.gov/ct2/show/NCT03022851
Google Scholar
Heidenreich, PA, Bozkurt, B, Aguilar, D, Larry Allen, A, Joni Byun, J, Monica Colvin, M et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation 2022; 145: e895–1032.Google Scholar
Fukuta, H, Little, WC. The cardiac cycle and the physiologic basis of left ventricular contraction, ejection, relaxation, and filling. Heart Fail Clin 2008; 4: 1–11.CrossRefGoogle ScholarPubMed
Feldman, T, Komtebedde, J, Burkhoff, D, et al. Transcatheter interatrial shunt device for the treatment of heart failure: rationale and design of the randomized trial to REDUCE elevated left atrial pressure in heart failure (REDUCE LAP-HF I). Circ Heart Fail 2016; 9: e003025.CrossRefGoogle ScholarPubMed
Malek, F, Neuzil, P, Gustafsson, F, et al. Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant. Int J Cardiol 2015; 187: 227–228.CrossRefGoogle ScholarPubMed
Søndergaard, L, Reddy, V, Kaye, D, Malek, F, Walton, A, Mates, M, et al. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail 2014; 16: 796–801.CrossRefGoogle ScholarPubMed
The AFteR registry–follow-up study to monitor the efficacy and safety of the Occlutech AFR in heart failure patients. Clinicaltrials.gov identifier: NCT04405583. Accessed January 10, 2023.Google Scholar
Bakhshaliyev, N, Ozdemir, R. The impact of atrial flow regulator implantation on hemodynamic parameters in patients with heart failure. Kardiologiia 2021; 61: 71–80.CrossRefGoogle ScholarPubMed
Butera, G, Piccinelli, E, Kolesnik, A, Averin, K, Seaman, C, Castaldi, B et al. Implantation of atrial flow regulator devices in patients with congenital heart disease and children with severe pulmonary hypertension or cardiomyopathy—an international multicenter case series. Front Cardiovasc Med 2024; 10: 1332395.CrossRefGoogle ScholarPubMed
Castaldi, B, Cuppini, E, Sirico, D, Cattapan, I, Fumanelli, J, Pozza, A, et al. Feasibility, safety, and efficacy of the atrial flow regulator in pediatric patients: a single-center experience. J Soc Cardiovasc Angiogr Interventions 2023; 2: 101209.CrossRefGoogle ScholarPubMed
Maron, BJ, Towbin, JA, Thiene, G, et al. American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement. Circulation 2006; 1113: 1807–1816.CrossRefGoogle Scholar
Lewis, AB. Clinical profile and outcome of restrictive cardiomyopathy in children. Am Heart J 1992; 123: 1589–1593.CrossRefGoogle ScholarPubMed
Cetta, F, OLeary, PW, Seward, JB, Driscoll, DJ. Idiopathic restrictive cardiomyopathy in childhood: diagnostic features and clinical course. Mayo Clin Proc 1995; 70: 634–640.CrossRefGoogle ScholarPubMed
Weller, RJ, Weintraub, R, Addonizio, LJ, Chrisant, MRK, Gersony, WM, Hsu, DT. Outcome of idiopathic restrictive cardiomyopathy in children. Am J Cardiol 2002; 90: 501–506.CrossRefGoogle ScholarPubMed
Rivenes, SM, Kearney, DL, Smith O’Brian, E, Towbin, JA, Denfield, SW. Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. Circulation 2000; 102: 876–882.CrossRefGoogle ScholarPubMed
Webber, SA, Lipshultz, SE, Sleeper, LA, et al. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype. Circulation 2012; 126: 1237–1244.CrossRefGoogle ScholarPubMed
Burlacu, A, Simion, P, Nistor, I, Covic, A, Tinica, G. Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review heart. Heart Fail Rev 2019; 24: 793–803.CrossRefGoogle Scholar
Rosalia, L, Ozturk, C, Shoar, S, Fan, Y, Malone, G, Cheema, FH, et al. Device-based solutions to improve cardiac physiology and Hemodynamics in Heart Failure with preserved ejection fraction. Jacc Basic Transl Sci 2021; 6: 772–795.CrossRefGoogle ScholarPubMed
Hansmann, G, Sabiniewicz, A, Sabiniewicz, R. Atrial flow regulator for postcapillary pulmonary hypertension: first-in-human transcatheter AFR device implantations in RCM. JACC Case Rep 2022; 4: : 878–884.CrossRefGoogle ScholarPubMed
Castaldi, B, Padalino, M, Sirico, D, Guariento, A, Vida, V, Di Salvo, G. Hybrid approach for end-stage heart failure treatment in a 6-month-old baby. Cardiol Young 2023; 33: 1738–1740.CrossRefGoogle Scholar
Abman, SH, Hansmann, G, Archer, SL, Ivy, DD, Adatia, I, Chung, WK et al. American Heart Association Council on Cardiopulmonary CCP, Resuscitation, Council on Clinical C, Council on Cardiovascular Disease in the Y, Council on Cardiovascular R, Intervention, Council on Cardiovascular S, Anesthesia, and the American Thoracic S. Pediatric pulmonary hypertension: Guidelines from the American heart association and American thoracic society. Circulation 2015; 132: 2037–2099.CrossRefGoogle Scholar
Mukherjee, D, Konduri, GG. Pediatric pulmonary hypertension: definitions, mechanisms, diagnosis, and treatment. Compr Physiol 2021; 11: 2135–2190.CrossRefGoogle ScholarPubMed
Rosenzweig, EB, Abman, SH, Adatia, I, Beghetti, M, Bonnet, D, Haworth, S, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J 2019; 53: 1801916.CrossRefGoogle ScholarPubMed
Lam, CS, Roger, VL, Borlaug, BA, Rodeheffer, RJ, Enders, FT, Redfield, MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009; 53: 1119–1126.CrossRefGoogle ScholarPubMed
Marc, H, Gabor, K, Marius Hoeper, M et al. ESC/ERS Scientific Document Group, 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 2022; 43: 3618–3731.Google Scholar
Saouti, N, Westerhof, N, Helderman, F, Marcus, JT, Stergiopulos, N, Westerhof, BE, et al. RC time constant of single lung equals that of both lungs together: a study in chronic thromboembolic pulmonary hypertension. Am J Physiol Heart Circ Physiol 2009; 297: H2154–H2160.CrossRefGoogle ScholarPubMed
Sanz, J, García-Alvarez, A, Fernández-Friera, L, et al. Right ventriculo-arterial coupling in pulmonary hypertension: a magnetic resonance study. Heart 2012; 98: 238–243.CrossRefGoogle ScholarPubMed
Takatsuki, S, Yanai, S, Ikehara, S, Nakayama, T, Matsuura, H. Clinical effects of syncope on disease severity and adverse outcomes in children with idiopathic and heritable pulmonary arterial hypertension. Pediatr Cardiol 2019; 40: 209–214.CrossRefGoogle ScholarPubMed
Bauer, A, Khalil, M, Schmidt, D, et al. Creation of a restrictive atrial communication in pulmonary arterial hypertension (PAH): effective palliation of syncope and end-stage heart failure. Pulm Circ 2018; 8: 1–9.CrossRefGoogle ScholarPubMed
Khan, MS, Memon, MM, Amin, E, Yamani, N, Khan, SU, Figueredo, VM, et al. Use of balloon atrial septostomy in patients with advanced pulmonary arterial hypertension: a systematic review and meta-analysis. Chest 2019; 156: 53–63.CrossRefGoogle ScholarPubMed
Kerstein, D, Levy, PS, Hsu, DT, Hordof, AJ, Gersony, WM, Barst, RJ. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995; 91: 2028–2035.CrossRefGoogle ScholarPubMed
Rajeshkumar, R, Pavithran, S, Sivakumar, K, Vettukattil, JJ. Atrial septostomy with a predefined diameter using a novel occlutech atrial flow regulator improves symptoms and cardiac index in patients with severe pulmonary arterial hypertension. Catheter Cardiovasc Interv 2017; 90: 1145–1153.Google ScholarPubMed
Youssef, DE, Averin, K, Richards, S, Sheppard, C, Seaman, C, Pietrosanu, M, et al. A North American, single-center experience implanting fenestrated atrial devices and atrial flow regulators into a heterogeneous group of pediatric pulmonary hypertension patients. Front Pediatr 2023; 11: 1073336.CrossRefGoogle ScholarPubMed
Gewillig, M, Brown, S. The Fontan circulation after 45 years: update in physiology. Heart 2016; 102: 1081–1086.CrossRefGoogle ScholarPubMed
Rychik, J, Fogel, MA, Donofrio, MT, Goldmuntz, E, Cohen, MS, Spray, TL, et al. Comparison of patterns of pulmonary venous blood flow in the functional single ventricle heart after operative aortopulmonary shunt versus superior cavopulmonary shunt. Am J Cardiol 1997; 80: 922–926.CrossRefGoogle ScholarPubMed
Laine, GA, Katz, AJ, Gabel, JC, Drake, RE. Effects of systemic venous pressure elevation on lymph flow and lung oedema formation. J Appl Physiol 1986; 6: 1634–1638.CrossRefGoogle Scholar
Itkin, M, Piccoli, DA, Nadolski, G, Rychik, J, DeWitt, A, Pinto, E, et al. Protein-losing enteropathy in patients with congenital heart disease. J Am Coll Cardiol 2017; 69: 2929–2937.CrossRefGoogle ScholarPubMed
Hraška, V. Decompression of thoracic duct: new approach for the treatment of failing fontan. Ann Thorac Surg 2013; 96: 709–711.CrossRefGoogle ScholarPubMed
Albal, PG, Menon, PG, Kowalski, W, Undar, A, Turkoz, R, Pekkan, K. Novel fenestration designs for controlled venous flow shunting in failing Fontans with systemic venous hypertension. Artif Organs 2013; 37: 66–75.CrossRefGoogle ScholarPubMed
Manuri, L, Calaciura, RE, de Zorzi, A, Oreto, L, Raponi, M et al. Atrial flow regulator for failing Fontan circulation: An initial European experience. Interact Cardiovasc Thorac Surg 2013; 27: 66–75.Google Scholar
Pascall, E, Jones, MI, Savis, A, Rosenthal, E, Qureshi, SA. Transcatheter creation of a pulmonary artery to left atrial fenestration in a failing Fontan circulation using the Atrial Flow Regulator (AFR). Cardiol Young 2021; 31: 1376–1379.CrossRefGoogle Scholar
Rafał, S, Anna, MK, Joanna, M, Paweł, D, Tomasz, M. Creation of the secondary fenestration in the inferior vena cava stump with the Occlutech Atrial Flow Regulator implantation in a Fontan patient. Kardiol Pol 2024; 82: 668–669.Google Scholar
Mehta, C, Jones, T, De Giovanni, JV. Percutaneous Transcatheter Communication Between the Pulmonary Artery and Atrium Following an Extra-Cardiac Fontan: An Alternative Approach to Fenestration Avoiding Conduit Perforation. Catheter Cardiovasc Interv 2008; 71: 936–939.Google Scholar
Kenny, D, McMahon, C, Walsh, KP. Transhepatic approach for extracardiac inferior cavopulmonary connection stent fenestration. Congenit Heart Dis 2011; 6: 276–279.CrossRefGoogle ScholarPubMed
Vyas, H, Driscoll, DJ, Cabalka, AK, Cetta, F, Hagler, DJ Results of transcatheter Fontan fenestration to treat protein losing enteropathy. Catheter Cardiovasc Interv. 2007; 69: 584–589.Google ScholarPubMed
Piccinelli, E, Castro-Verdes, MB, Fraisse, A, Carles, BR. Implantation of an Atrial Flow Regulator in a Child on Venoarterial Extracorporeal Membrane Oxygenator as a Bridge to Heart Transplant: A Case Report. J Card Fail. 2021; 27: 364–367.CrossRefGoogle Scholar
Piliero, N, Bedague, D, Fournel, E, Saunier, C
Bouvaist, H. The Atrial Flow Regulator: A Novel Device for Left Ventricular Unloading in Patients Receiving Venoarterial Extracorporeal Membrane Oxygenation Support? Chest 2021; 160: e165–e167.CrossRefGoogle ScholarPubMed
Bautista-Rodriguez, C, Hascoët, S, Fraisse, A. Feasibility, safety, and efficacy of Atrial FlowRegulator in children under 10 kg. Catheter Cardiovasc Interv 2023. doi: 10.1002/ccd.30536.Google Scholar
Veeram Reddy, SR, Guleserian, KJ, Nugent, AW. Transcatheter removal of atrial septal stent placed to decompress left atrium with VA ECMO. Catheter Cardiovasc Interv 2015; 85: 1021–1025.Google ScholarPubMed
Paitazoglou, C, Bergmann, MW. The atrial flow regulator: current overview on technique and first experience. Ther Adv Cardiovasc Dis 2020.14: 1753944720919577.CrossRefGoogle ScholarPubMed
Andreas, F, Harald Kühl, P. The Role of Antiplatelet Agents in the Management of Patients Receiving Intracardiac Closure Devices. Curr Pharm Des 2006; 12: 1287–1291.Google Scholar
Seipelt, RG, Franke, A, Vazquez-Jimenez, JF, Hanrath, P, von Bernuth, G, Messmer, BJ, et al. Thromboembolic complications after Fontan procedures: Comparison of different therapeutic approaches. Ann Thorac Surg 2002; 74: 556–562.CrossRefGoogle ScholarPubMed
Rebecca, B, Vera, I, Paul, M, et al. Anticoagulation during ECMO in neonatal and paediatric patients. Thromb Res 2019; 173: 172–177.Google Scholar
Sonawane, BS, Sivakumar, K. Transcatheter reduction in size of large undesirable fenestrations following extracardiac conduit Fontan surgery with off-label use of Occlutech atrial flow regulator. Ann Pediatr Cardiol 2020; 13: 260–263.Google ScholarPubMed